Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Vincentage Pharma Co., Ltd
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07360275CT.gov A Study of VCT220 in Participants With Hypertension and Obesity or Overweight | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hypertensive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cx11 (this asset) | Vincentage Pharma Co., Ltd | P2 | CCC · 53 |
| Valsartan | University of Alabama at Birmingham | P4 | BBB |
| Hydrochlorothiazide | University of Kansas Medical Center | P4 | BBB |
| Losartan | Rong Zhang | P4 | BBB |
| Amlodipine | Jing Liu | P4 | BBB |
| Corpril | University of Michigan | P4 | BBB |
| Olmesartan Medoxomil | Virginia Polytechnic Institute and State University | P4 | BBB |
| Trandolapril | University of Florida | P4 | BBB |
| Cilnidipine | Boryung Pharmaceutical Co., Ltd | P4 | BBB |
+42 more in the Hypertensive Disorder cohort
Other indications for cx11
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Obesity Disorder | — | P3 | B · 58 |
| Type 2 Diabetes Mellitus | — | P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cx11 in Hypertensive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cx11-hypertensive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →